Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 79 of the 80 references it cites were found in a registry or an index.

Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade

Published version of a preprint

Abstract

Purpose: Response rates to immune checkpoint blockade (ICB; anti-PD-1/anti-CTLA-4) correlate with the extent of tumor immune infiltrate, but the mechanisms underlying the recruitment of T cells following therapy are poorly characterized. A greater understanding of these processes may see the development of therapeutic interventions that enhance T-cell recruitment and, consequently, improved patient outcomes. We therefore investigated the chemokines essential for immune cell recruitment and subsequent therapeutic efficacy of these immunotherapies. Experimental Design: The chemokines upregulated by dual PD-1/CTLA-4 blockade were assessed using NanoString-based analysis with results confirmed at the protein level by flow cytometry and cytometric bead array. Blocking/neutralizing antibodies confirmed the requirement for key chemokines/cytokines and immune effector cells. Results were confirmed in patients treated with immune checkpoint inhibitors using single-cell RNA-sequencing (RNA-seq) and paired survival analyses. Results: The CXCR3 ligands, CXCL9 and CXCL10, were significantly upregulated following dual PD-1/CTLA-4 blockade and both CD8+ T-cell infiltration and therapeutic efficacy were CXCR3 dependent. In both murine models and patients undergoing immunotherapy, macrophages were the predominant source of CXCL9 and their depletion abrogated CD8+ T-cell infiltration and the therapeutic efficacy of dual ICB. Single-cell RNA-seq analysis of patient tumor-infiltrating lymphocytes (TIL) revealed that CXCL9/10/11 was predominantly expressed by macrophages following ICB and we identified a distinct macrophage signature that was associated with positive responses to ICB. Conclusions: These data underline the fundamental importance of macrophage-derived CXCR3 ligands for the therapeutic efficacy of ICB and highlight the potential of manipulating this axis to enhance patient responses.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-19-1868

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 80 references

Cited by

See all 800

Metadata

Authors
House, I. G., Savas, P., Lai, J., Chen, A. X. Y., Oliver, A. J., Teo, Z. L., Todd, K. L., Henderson, M. A., Giuffrida, L., Petley, E. V., Sek, K., Mardiana, S., Gide, T. N., Quek, C., Scolyer, R. A., Long, G. V., Wilmott, J. S., Loi, S., Darcy, P. K., & Beavis, P. A.
Affiliations
  • The University of Melbourne (AU)
  • The University of Sydney (AU)
Venue
Clinical Cancer Research
Published
2020-01-15
Volume
26
Issue
2
Pages
487-504
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2982017357
Cited by
790
References
80
Citations by year
2026: 165 · 2025: 141 · 2024: 140 · 2023: 119 · 2022: 105 · 2021: 83 · 2020: 36
FWCI
23.51
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • NHMRC (1132373, APP1136680)
  • National Breast Cancer Foundation (IIRS-19-016 19-22, ID# ECF-17-005)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Keywords
CXCL9, CXCL10, CXCL11, CXCR3 ligands, macrophages, immune checkpoint blockade, anti-PD-1, anti-CTLA-4, CD8+ T cell infiltration, tumor immune microenvironment, chemokines, tumor-infiltrating lymphocytes, antitumor immunity
MeSH terms
Animals, Immunotherapy, Macrophages, Mice, Inbred C57BL, Neoplasms, CD8-Positive T-Lymphocytes, Cell Line, Tumor, Mice, Chemokine CXCL10, Receptors, CXCR3, Chemokine CXCL9, Tumor Microenvironment, CTLA-4 Antigen, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-1868
The paper
House, I. G., Savas, P., Lai, J., Chen, A. X. Y., Oliver, A. J., Teo, Z. L., Todd, K. L., Henderson, M. A., Giuffrida, L., Petley, E. V., Sek, K., Mardiana, S., Gide, T. N., Quek, C., Scolyer, R. A., Long, G. V., Wilmott, J. S., Loi, S., Darcy, P. K., & Beavis, P. A. (2020). Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-1868

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.